Advertisement

Topics

FDA Approves Triptodur for Treatment of Patients 2 Years and Older with Central Precocious Puberty

09:47 EDT 30 Jun 2017 | Speciality Pharma Journal

ATLANTA and LAUSANNE, Switzerland, June 30, 2017 /PRNewswire/ — Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, and Debiopharm International SA, part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Triptodur™ for the treatment of pediatric patients 2 years and older with central …

Original Article: FDA Approves Triptodur for Treatment of Patients 2 Years and Older with Central Precocious Puberty

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Triptodur for Treatment of Patients 2 Years and Older with Central Precocious Puberty"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...